Optimizing Natalizumab in MS: A Systematic Review of Dosing Strategies and Discontinuation Outcomes Across Treatment Paradigms
This PICO-based systematic review assesses natalizumab's effectiveness in MS through three key comparisons: (1) dosing interval optimization, (2) discontinuation outcomes, and (3) efficacy benchmarks against untreated disease. Outcomes focus on relapse rates and disability trajectories using trial and real-world data.
Publication Details
- Journal
- Open Science Framework
- Published
- 2025-01-01
- DOI
- https://doi.org/10.17605/osf.io/wn5xr
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00